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Use of obstetrical interventions in the periviable period is more likely when parents 3 
desire active resuscitation and increases odds of survival to discharge from the NICU.  4 
 5 
Short title: 6 
Obstetrical Management at the Threshold of Viability 7 
 8 
AJOG at a Glance: 9 
 10 
A. This study was conducted to review the use of obstetrical interventions in 11 
multiple academic centers in the U.S. in deliveries prior to 25 weeks gestation, 12 
and to assess the odds of survival based on their usage.   13 
B. Interventions were more likely to be used when resuscitation was desired.  14 
Increased survival was noted when pharmacologic interventions were bundled 15 
for deliveries occurring at 23 and 24 weeks gestation. 16 
C. This study provides data on use of obstetrical interventions for management of 17 
pregnancies with threatened delivery prior to 25 weeks, including 22 week 18 
management, when interventions are more controversial.    19 
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 4 
Background:  Despite medical advances in the care of extremely preterm neonates, and 5 
growing acceptance of resuscitation at 23 and even 22 weeks’ gestation, controversy 6 
remains concerning use of antepartum obstetrical interventions intended to improve 7 
outcomes in the setting of anticipated extremely preterm birth. In the absence of 8 
demonstrated benefit prior to 23 weeks, and with uncertain benefit at 23 weeks, prior 9 
obstetric committee opinions have advised against their use at these gestational ages. 10 
 11 
Objectives:  12 
• To review the use of obstetrical interventions at the threshold of viability based 13 
on neonatal resuscitation plan 14 
• To review the odds of survival to NICU discharge based on use of obstetrical 15 
interventions while adjusting for neonatal factors  16 
 17 
Study Design:  18 
This retrospective study of 6 study centers reviewed pregnant patients admitted 19 
between 22 0/7 and 24 6/7 weeks facing delivery from 2011 to 2015.  Patients with 20 
known anomalies or missing data were excluded. Records were reviewed for 21 
demographics, resuscitation plan, and obstetrical interventions.  Mode of delivery, 22 
delivery room care, and final infant dispositions were recorded. Multiple gestations 23 
were included as one pregnancy in regard to the use of obstetrical interventions and 24 
were excluded from survival analysis.   25 
 26 
Results:  27 
478 mothers met inclusion criteria. When resuscitation was planned, mothers were 28 
more likely to receive all conventional obstetrical interventions (antenatal steroids, 29 
magnesium sulfate for neuroprotection, tocolytics, and Group Beta Streptococcus 30 
prophylaxis) regardless of gestational age at admission and were more likely to be 31 
delivered by cesarean section (p<0.05).  Analyzed as a group, when antenatal steroids, 32 
magnesium sulfate, tocolytics and GBS prophylaxis were administered, the odds of 33 
survival to NICU discharge increased for newborns born at 22 weeks (OR 11.33, CI 1.405-34 
91.4) and 23 weeks gestation (OR 15.5, CI 3.747-64.11) (p<0.05).  In singletons, the odds 35 
of survival to NICU discharge was not improved by cesarean delivery versus vaginal 36 
delivery even after adjusting for use of additional interventions, weight, gender and 37 
gestational age (OR1.0, CI 0.59-1.8, p=0.912). 38 
 39 
Conclusion:  40 
In this study, when postnatal resuscitation was planned at 22 and 23 weeks gestation, 41 
women were more likely to receive antenatal steroids, magnesium sulfate, and 42 
antibiotics; provision of this bundle imparted survival benefit at 23 weeks but could not 43 
be demonstrated at 22 weeks due to small sample size. These findings support of 44 
 4 
neonate-oriented obstetric interventions in the setting of delivery at 23 weeks when 1 
resuscitation is planned, and further exploration of optimal obstetric care when 2 












































Periviable deliveries, occurring between approximately 20 0/7 weeks to 25 6/7 2 
weeks, account for less than 1% of all births, but in some studies, up to 40% of all infant 3 
deaths [1-3].  While higher rates of neonatal active treatment have been shown to 4 
increase survival at the lowest gestational ages, obstetric interventions for these 5 
extremely premature infants have shown negligible improvement in survival rates and 6 
neurodevelopmental impairment [4] and  clear guidelines for management are lacking 7 
[2, 4, 5].  Even without clear guidelines, some centers continue to push the boundaries 8 
for interventions in these extremely premature infants.  9 
Common obstetrical interventions used for both prolongation of pregnancy and 10 
improvement of neonatal outcomes include antenatal steroids, tocolytics, magnesium 11 
sulfate for neuroprotection, antibiotics for Group Beta Streptococcus (GBS) prophylaxis, 12 
and cesarean delivery [6].  While the benefits of antenatal steroids have been 13 
documented, substantial uncertainty surrounds the benefit of the remainder of 14 
interventions for improving outcomes for extremely preterm infants, creating a 15 
potential disconnect between evidence-based obstetric recommendations and neonatal 16 
practice [1-4].  Some new studies also suggest benefits of antenatal steroids alone at 17 
these extremely early gestational ages with benefits seen following a full course of 18 
steroids as early as 22 weeks [7].  Therefore, the goal of this study was to evaluate the 19 
use of these interventions for pregnancies with threatened delivery between 22 0/7 to 20 
24 6/7 weeks gestational age based on plans for resuscitation following delivery, and to 21 
determine the impact of these interventions on infant survival.  Although these 22 
 6 
interventions are not recommended, they are nonetheless utilized. We sought to 1 
understand the utilization of pharmacologic interventions for women based on their 2 
gestational-week of admission and neonatal consequences related to utilizing these 3 
interventions.  We propose that while these interventions are not recommended at 4 
earlier gestational ages, they are nonetheless utilized, especially when resuscitation is 5 
planned for these early neonates.   6 
 7 
Materials and Methods 8 
We conducted a multi-center retrospective study consisting of INDEED 9 
(Investigating Neonatal Decisions for Extremely Early Deliveries) study group centers 10 
with data collected from January 1, 2011 to December 31, 2015.  The primary aim of the 11 
INDEED study group was to understand conditions around decisions for active delivery 12 
room treatment for those pregnancies deliveries between 22 0/7 to 24 6/7 weeks 13 
gestational age.  All participating hospitals were part of tertiary academic medical 14 
referral centers providing tertiary high-risk obstetric and neonatal care to high-risk 15 
obstetric patients.  The Institutional Review Board reviewed and approved waiver of 16 
consent for this study at each individual site.  A grant from North Shore University 17 
Health System supported use of the REDCap database [8].   18 
Study Population 19 
Both obstetrical and neonatal databases were reviewed for patients presenting 20 
between 22 0/7 to 24 6/7 weeks gestational age with a living fetus with threatened 21 
preterm delivery and delivering before 25 weeks; those who remained pregnant beyond 22 
 7 
this periviable period were excluded.  Women were excluded from the study if their 1 
fetus had a known major congenital or genetic anomaly.  Women were analyzed by 2 
interventions received, regardless of singleton or multiple gestation to gauge rates of 3 
interventions or condition at delivery.   4 
Study Institutions 5 
Study institutions were located across the central regions of the United States.  6 
Resuscitation plans based on individual centers have previously been published by Dalia 7 
et al noting varying levels of resuscitation for all gestational age groups except those at 8 
24 weeks.  At 25 weeks gestational age, all interventions were provided for infants 9 
including resuscitation. During this review period, at two centers, options offered for 10 
newborn care at 22 completed weeks reportedly varied by neonatologists. Three had 11 
agreed-upon approaches by neonatology, and one had a written policy; of these 12 
centers, two offered only comfort care and two recommended comfort care but would 13 
provide resuscitation per parent request. Obstetric care for planned neonatal 14 
resuscitation was not standardized. The six centers were analyzed as having higher and 15 
lower resuscitation rates, based on significantly different rates of resuscitation at 22 and 16 
23 completed weeks [9].  17 
 18 
Data Collection 19 
Records were reviewed for maternal demographic and medical information, plan 20 
of care for resuscitation through neonatal and/or obstetrical documentation and use of 21 
obstetric interventions and neonatal characteristics.  Interventions reviewed include: 22 
 8 
antenatal steroids (at least one dose prior to delivery), magnesium sulfate for 1 
neuroprotection, tocolytics (indomethacin, nifedipine, terbutaline or magnesium for 2 
tocolysis), antibiotics for GBS prophylaxis, and mode of delivery.  For cesarean section, 3 
documented indications included fetal distress, fetal malpresentation, maternal well-4 
being, a combination of the above, or unknown.  Primary outcome of death vs. survival 5 
to NICU discharge of newborn was reported per each pregnancy. 6 
Delivery room care was reviewed from both obstetrical and neonatal 7 
documentation.  Gender, gestational age at delivery, and delivery weight (in grams) 8 
were collected as covariates.  Documentation of delivery room resuscitation plan, 9 
(initiation of comfort care or neonatal resuscitation) was reviewed.   Neonatal condition 10 
at delivery and death or survival to NICU discharge home were noted.  Infants 11 
transferred to another center were not counted as having confirmed survival to NICU 12 
discharge, as their ultimate disposition was unknown.    13 
Statistical Analysis 14 
Descriptive statistics were calculated for the overall population and also for each 15 
gestational week at 22, 23 and 24 weeks.  Summary statistics describing maternal 16 
characteristics compared to interventions used, stratified by the completed weeks 17 
gestation on presentation.  Groups were analyzed using independent t-tests for 18 
continuous variables and chi-squared tests for categorical variables.  Generalized linear 19 
models were created to note differences between intervention and non-intervention 20 
groups for antenatal steroids, magnesium sulfate, and GBS prophylaxis.  Generalized 21 
linear mixed models were generated for differences between intervention and control 22 
 9 
groups and included a random effect for the institution to account for the effect of 1 
different sites involved in the study.    2 
Effects of obstetric interventions on survival to NICU discharge adjusted for 3 
neonatal characteristics were analyzed in step-wise manner.  All newborns delivered 4 
between 22 and 24 completed weeks gestation for whom resuscitation was planned 5 
were analyzed first as one group, then by each gestational week.  Multivariable logistic 6 
regression analyses evaluated effects of pharmacologic obstetric interventions, 7 
adjusting for neonatal characteristics, on survival to NICU discharge.  Specifically, in our 8 
overall survival model for all 412 newborns with planned resuscitation, the effects on 9 
survival to discharge of the following variables were examined: receipt of any antenatal 10 
steroids, magnesium for neuroprotection, tocolytics, antibiotics for GBS prophylaxis and 11 
delivery by cesarean section, adjusting for neonatal factors known to influence survival
:
 12 
singleton status, sex, gestational age at delivery, and birthweight in grams.  We 13 
subsequently modeled the effect of each pharmacologic intervention on survival to 14 
NICU discharge, controlling for neonatal factors.  Post-hoc analyses to further examine 15 
findings at 24 weeks are explained in that section.  Statistical analyses were performed 16 
using SAS, version 9.4 (SAS Institute, Cary, NC) and SigmaStat 4.0 (Systat Software Inc., 17 
San Jose, CA).  P-values <0.05 were considered significant. 18 
 19 
Results 20 
478 pregnant women met inclusion criteria after 8 were excluded for fetuses 21 
with anomalies and 10 were excluded for missing medical records despite identification 22 
 10
in a database. Approximately one-third of these patients were nulliparous, with an 1 
average maternal age of 27.3 years.  Gestational age at mother’s admission ranged from 2 
22 0/7 to 24 6/7 weeks, with mean and standard deviation 23 3/7 + 6 days.  Gestational 3 
age at delivery (of twin A if multiple gestation) also ranged from).  There were 398 4 
singleton pregnancies with the remaining 80 comprised of twins (n=74 mothers) and 5 
higher order multiples (n=8 mothers).   6 
Frequency of Obstetric Interventions by gestational age at admission 7 
Baseline characteristics of women and receipt of obstetrical interventions are 8 
shown in Table 1.  To understand the progression of care for women admitted at these 9 
early ages, we report here interventions received based on the gestational age at which 10 
women were first admitted.  (In contrast, information on prevalence of interventions 11 
based on week of delivery are found in Table 2.)  For the cohort, and for every 12 
gestational age group by week a plan for resuscitation was the most consistent factor 13 
associated with increased likelihood for receiving obstetric interventions. Maternal age, 14 
parity, and marital status did not appear to impact provision of these interventions.  15 
Estimated fetal weight was unknown prior to delivery for 27% (129 of 478) of women.   16 
A higher mean birthweight was also noted for those infants whose mothers received 17 
antenatal steroids, magnesium sulfate, and tocolytics.    18 
Women admitted at 22 weeks gestation  19 
143 pregnant women were admitted between 22 0/6 and 22 6/7; 33% (n=47) 20 
received at least one dose of steroids, 27% (n=38) received magnesium sulfate, 24% 21 
(n=34) received antibiotics for GBS prophylaxis, and 18% (n=26) received tocolytics prior 22 
 11
to delivery.  Among those admitted at 22wks, 48% had a plan for resuscitation, and 1 
infants were delivered at 22 weeks (n=95), 23 weeks (n=33), and 24 weeks (n=15).  2 
Women planning neonatal resuscitation were more likely to receive steroids (p<0.05), 3 
magnesium sulfate (p<0.05), and GBS prophylaxis (p<0.05), but not tocolytics compared 4 
to those women not planning on neonatal resuscitation.  Most (90%) of 22 week 5 
deliveries occurred vaginally.  Cesarean section was performed in 20% (14 of 69) of 6 
cases in which neonatal resuscitation was planned and never when no resuscitation was 7 
planned (Table 1). The majority of these cases (12 of 14) were in the case of multiple 8 
gestations with the indication for singleton deliveries including malpresentation and 9 
maternal well-being. 10 
Women admitted at 23 weeks gestation 11 
197 pregnant women were admitted between 23 0/7 and 23 6/7; 72% (n=142) 12 
received at least one dose of steroids, 60% (n=118) received magnesium sulfate, 42% 13 
(n=84) received antibiotics for GBS prophylaxis, and 34% (n=68) received tocolytics prior 14 
to delivery, with planned resuscitation for 82% of infants.  Among those admitted at 23 15 
weeks, 117 delivered at 23 weeks and 80 delivered at 24 weeks.  Women planning 16 
neonatal resuscitation were significantly more likely to receive all four interventions.  17 
Sixty-one percent of these pregnancies were delivered vaginally (n=117) with an 18 
increase in cesarean sections when neonatal resuscitation was planned (n=75 planned 19 
resuscitation, n=3 no resuscitation planned).  Singleton deliveries accounted for 35% of 20 
cesarean deliveries with the  most common indication being malpresentation (10 of 26). 21 
Women admitted at 24 weeks gestation   22 
 12
138 women were admitted between 24 0/7 and 24 6/7; 81% (n=112) received at 1 
least one dose of steroids, 77% (n=106) received magnesium sulfate, 44% (n=61) 2 
received antibiotics for GBS prophylaxis, and 33% (n=46) received tocolytics prior to 3 
delivery, with planned resuscitation for 96% of infants.  All patients planning 4 
resuscitation received steroids.  Thirty-eight percent of pregnancies presenting at 24 5 
weeks were delivered vaginally (n=42).    Singleton deliveries accounted for 75% of 6 
cesarean deliveries with the  most common indication being malpresentation (43 of 7 
120).  All patients included delivered prior to 25 weeks gestational age.  8 
Impact of pharmacologic obstetrical interventions on confirmed survival to NICU 9 
discharge  10 
Neonatal resuscitation was planned for 304 of the 397 mothers’ newborns: 48%, 11 
82%, and 96% at 22 weeks, 23 weeks, and 24 weeks gestational age, respectively.  12 
Receipt of maternal obstetric interventions and neonatal characteristics and outcomes 13 
for the 412 newborns with planned resuscitation are found in Table 2.  Four-hundred 14 
twelve newborns had resuscitation planned; all but 13 (3%) were liveborn and admitted 15 
to the NICU.   Because the ultimate dispositions for 13 NICU patients transferred outside 16 
facilities were not known, the confirmed survival to discharge home from the NICU for 17 
the entire group of newborns with resuscitation planned was admitted to the NICU was 18 
45% (187 of 412).   19 
For the entire group of 412 newborns with planned resuscitation, in the model 20 
analyzing survival as a function of maternal receipt of the 5 obstetric interventions 21 
(steroids, magnesium, tocolytics, GBS prophylaxis, cesarean delivery) and four neonatal 22 
 13
factors (gestational age, birthweight by week-specific study population quartiles, sex, 1 
and singleton status), three variables—steroids, gestational age, and birthweight—were 2 
significant.   Amongst newborns with planned resuscitation, odds of confirmed survival 3 
to NICU discharge were 2.6 times higher for those whose mothers received antenatal 4 
steroids (CI: 1.3-5.6, p=0.011), after adjusting for the two other factors significant in the 5 
model—gestational age and birthweight.   6 
In models analyzing the effect each medicinal intervention had on odds of 7 
survival while adjusting for the neonatal variables (age, sex, singleton, birthweight), 8 
again, only steroids were found to be significantly associated with survival to discharge 9 
(OR 2.7, CI: 1.5-4.9, p=0.002).   10 
Newborns delivered 22 0/7 to 22 6/7 weeks 11 
At 22 weeks, 36 of 40 newborns with planned resuscitation were liveborn, and 12 
condition of one was not known; 3 newborns were confirmed as surviving to discharge 13 
home.  The outcomes in relation to exposures to maternal receipt of perinatal 14 
medications are reported in Figure 1.  At 22 weeks, interventions did not result in 15 
significant differences in survival to home discharge, but sample size was small. 16 
Newborns delivered 23 0/7 to 23 6/7 weeks 17 
One-hundred twenty-two newborns delivered at 23 weeks had resuscitation planned; 18 
116 (95%) were liveborn; 42 (34%) survived to discharge home from NICU, and one baby 19 
was transferred to an outside facility.  As shown in Figure 1, for these newborns, the 20 
following interventions were associated with increased odds of confirmed survival to 21 
home from the NICU: antenatal steroids (OR 5.2, CI 1.8-14.6, p=0.002), magnesium (OR 22 
 14
4.3, CI 1.8-10.1, p=0.001, and bundle of receiving steroids, magnesium, GBS prophylaxis 1 
and tocolytics (OR 3.2, CI 1.2-8.7, p=0.037). 2 
 3 
Newborns delivered 24 0/7 to 24 6/7 weeks  4 
 Two-hundred fifty newborns delivered at 24 weeks had resuscitation planned; 5 
247 of these (99%) were liveborn.  Fifty-seven percent (142 newborns of 250) survived 6 
to discharge home from NICU, and 11 were transferred to an outside facility.  As seen in 7 
Figure 1, maternal receipt of obstetric interventions did not affect likelihood of survival 8 
to discharge home.  Because these findings differed dramatically from those found for 9 
newborns delivered at 23 weeks, post hoc analyses were performed.  The sample size of 10 
250 newborns allowed performance of multivariable analyses of calculating odds of 11 
survival with each intervention while adjusting for neonatal factors of gestational age, 12 
birthweight and, sex, and singleton status.   Birthweight was the only significant factor in 13 
these analyses.  More specifically, birthweight lower than the lowest week-specific 14 
study group quartile was associated with lower odds of survival.  However, as seen in 15 
Figure 2, the 24-week study population birthweight quartiles were markedly higher than 16 
even age-specific Fenton percentiles (average of male and female) [10], while those of 17 
the 23-week study population were closer to the Fenton percentiles.  This may partially 18 
explain the dominance of birthweight on odds of survival to NICU discharge at 24 weeks 19 
while pharmacologic interventions were significantly associated with higher survival 20 




Principal findings of this study 1 
In this study, we sought to review the utilization of pharmacologic obstetric 2 
interventions and short-term neonatal survival across six academic centers.   We found 3 
that when resuscitation was planned, mothers were more likely to receive all 4 
pharmacological interventions regardless of gestational age at admission.  They were 5 
also more likely to be delivered by cesarean section.    6 
Our findings suggest that, at these centers, obstetric practice is aligned with 7 
published obstetric practice guidelines at 24 weeks gestational age, but not at 22 and 23 8 
weeks [2].   While there is no clear evidence in current literature to support antenatal 9 
steroids, magnesium sulfate, antibiotics, and cesarean delivery at 22 and 23 weeks, we 10 
found some of these patients did receive these interventions, particularly antenatal 11 
steroids; not surprisingly, provision of some of these interventions - antenatal steroids, 12 
magnesium sulfate, antibiotics for GBS, and cesarean delivery -   was associated with a 13 
plan for neonatal resuscitation.   14 
Newborns with planned resuscitation whose mothers received antenatal 15 
steroids had increased chances of survival to discharge home from the NICU in logistic 16 
regression models for the group as a whole and at 23 weeks.  Unfortunately, our small 17 
sample size of 40 newborns delivered at 22 weeks precluded examining this group 18 
separately.  We did not identify survival benefit associated with provision of 19 
pharmacologic interventions at 24 weeks; we speculate that the unusual weight 20 
distribution in this group of neonates may have overshadowed the influence of these 21 
interventions on survival to NICU discharge. 22 
 16
Results  1 
Overall, our study findings are consistent with previous work demonstrating benefit of 2 
admission of antenatal steroids at earlier gestational ages.  Mori et al. of Japan noted 3 
improved survival when antenatal steroids were used at 22 and 23 weeks [11].  Similar 4 
findings were noted by Hayes et al in the US when antenatal steroids were given at 23 5 
weeks gestational age [12].    Study designs, however, have been small and 6 
retrospective and questions of equipoise may limit randomized controlled trials, leaving 7 
obstetricians with a lack of high-quality evidence or consensus on management.  There 8 
has also been controversy around the best mode of delivery for these extremely 9 
premature infants, largely over concerns for increased maternal morbidities.  Previous 10 
studies have shown little benefit to cesarean delivery over vaginal delivery prior to 24 11 
weeks gestational age, though many physicians continue to offer cesarean delivery prior 12 
to this point [6, 13-16] .  In our population, while cesarean delivery occurred in about 13 
half of deliveries overall, this had no significant effect on survival outcomes in the model 14 
examining all possible obstetric interventions and neonatal factors for newborns with 15 
planned resuscitation; closer examination of the impact of cesarean delivery is 16 
warranted as the aims of this study did not delve into the indications for cesarean 17 
deliveries.   18 
Clinical Implications  19 
As the care of extremely premature neonates becomes more advanced, we 20 
anticipated that while not recommended, use of these obstetrical interventions during 21 
this early gestational ages would continue based on the parents desire for neonatal 22 
 17
resuscitation.  We recognize that while these results may not coincide with the most 1 
recent joint committee recommendations, these results may be used for future 2 
guidelines and discussion between both obstetricians and neonatologists for 3 
management. 4 
While our findings demonstrate rates of interventions correlating to planned 5 
neonatal resuscitation at 22 weeks, our small cohort did not reveal statistically 6 
significant improvement in survival to NICU discharge.  Our review of recent studies  7 
reporting survival rate at this gestational week (See Supplemental Table 1) reveals 8 
vast differences in reported survival rates.  However, ours is the only study to our 9 
knowledge that reviews receipt of multiple interventions prior to delivery and 10 
impact on neonatal survival.  We believe this adds to the discussion among 11 
obstetricians and neonatologists to review best practices among these extremely 12 
premature infants.  13 
 14 
Research Implications  15 
As we continue to review both this data and current literature, there are several 16 
questions regarding best practice management for these periviable deliveries.  In the 17 
obstetric world, the role of cesarean section at these early gestational ages remains 18 
controversial prior to 24 weeks gestational ages.  While full review of indications of 19 
delivery and outcome associations was beyond the scope of this analysis, it continues to 20 
warrant further research.  We have also noticed differences among resuscitation 21 
 18
counseling and recognize this as an important area for further study.   1 
Strengths and Limitations 2 
While periviable deliveries make up a low percentage of preterm births, this 3 
study was able to include a large subset of deliveries across multiple perinatal centers.  4 
This robust group of data adds to current knowledge on management of these births 5 
and addresses both aspects of obstetric and neonatology management during the 6 
antepartum period.  We recognize limitations of our study.  Data were collected 7 
retrospectively from all study centers; prospective study might minimize missing data 8 
and more clarity about perinatal decision-making and neonatal outcome.  Finally, new 9 
data and recommendations on management released by prominent pediatric and 10 
obstetric organizations during this time period may have led to changes in physician 11 
practices since the years of our study [2, 6].   12 
Conclusions 13 
Despite its limitations, this study contributes findings from nearly 500 women 14 
delivering in the periviable period to continue the discussion among obstetric and 15 
neonatal providers for best practices for treating mothers presenting in these extremely 16 
early gestational ages.  While we do not offer a consensus for management at 22 and 23 17 
weeks gestational age, the disconnect between existing guidelines and obstetric 18 
practice in this large cohort emphasizes the complexity of perinatal medical decision 19 
making for women at risk for extremely preterm delivery, particularly those desiring 20 
resuscitation for their infants after birth. If neonatal resuscitation is offered and 21 
planned, it is logical to offer interventions with potential to improve neonatal outcomes; 22 
 19
our findings suggest a discomfort among obstetric providers to forego potentially 1 
beneficial interventions, even in the absence of strong evidence to support their use. 2 
The demonstration of survival benefit for infants at 23 weeks when their mothers 3 
received these interventions supports continued close examination of existing 4 
guidelines; small numbers of infants born and resuscitated at 22 weeks continues to 5 
complicate evidence-based perinatal decision making when deliver at this gestational 6 
age is anticipated.  7 
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Table I: Characteristics and Receipt of Obstetric Interventions of 478 pregnant women overall and by gestational age in weeks 
 
Overall (N = 478) 
 Antenatal Steroids  Magnesium sulfate  Tocolytics  GBS PPX  Mode of Delivery  
 Yes No  Yes No  Yes No  Yes No  Vaginal Cesarean  
Mother's age 27.7 (6.4) 27.0 (6.0)  27.0 (6.1) 27.6 (6.3)  26.6 (6.2) 27.5 (6.1)  27.3 (6.2) 27.2 (6.2)  27.2 (6.0) 27.4 (6.5)  
Birthweight 419.0 (240.8) 290.5 (196.1) ** 412.8 (242.0) 330.7 (216.5) ** 459.9 (231.3) 342.2 (228.5) ** 381.8 (247.5) 382.4 (228.1)  365.5 (226.9) 410.5 (247.3)  
Parity                
Nulliparous  (51.33%) 89 (50.28%)  139 (53.05%) 104 (48.37%)  78 (55.71%) 165 (48.96%)  92 (51.69%) 151 (50.50%)  157 (52.51%) 86 (48.31%)  
Multiparous 146 (48.67%) 88 (49.72%)  123 (46.95%) 111 (51.63%)  62 (44.29%) 172 (51.04%)  86 (48.31%) 148 (49.50%)  142 (47.49%) 92 (51.69%)  
Race/Ethnicity           *       
Caucasian 104 (34.67%) 46 (26.44%)  87 (33.46%) 63 (29.44%)  52 (37.41%) 98 (29.25%)  53 (29.78%) 97 (32.77%)  92 (30.98%) 58 (32.77%)  
African American 171 (57%) 107 (61.49%)  151 (58.08%) 127 (59.35%)  81 (58.27%) 197 (58.81%)  108 (60.67%) 170 (57.43%)  176 (59.26%) 102 (57.63%)  
Other 25 (8.33%) 21 (12.07%)  22 (8.46%) 24 (11.21%)  6 (4.32%) 40 (11.94%)  17 (9.55%) 29 (9.80%)  29 (9.76%) 17 (9.6%)  
Marital Status                  
Single 204 (67.77%) 121 (68.36%)  176 (67.18%) 149 (68.98%)  91 (65%) 234 (69.23%)  116 (64.8%) 209 (69.90%)  209 (69.67%) 116 (65.17%)  
Married 97 (32.23%) 56 (31.64%)  86 (32.82%) 67 (31.02%)  49 (35%) 104 (30.77%)  63 (35.2%) 90 (30.10%)  91 (30.33%) 62 (34.83%)  
Insurance     *       *       
Medicaid 178 (59.53%) 106 (60.92%)  151 (58.08%) 133 (62.44%)  75 (53.96%) 209 (62.57%)  101 (57.06%) 183 (61.82%)  173 (58.45%) 112 (63.28%)  
Private 106 (35.45%) 49 (28.16%)  95 (36.54%) 60 (28.17%)  58 (41.73%) 97 (29.04%)  65 (36.72%) 90 (30.41%)  96 (32.43%) 58 (32.77%)  
None 15 (5.02%) 19 (10.92%)  14(5.38%) 20 (9.39%)  6 (4.32%) 28 (8.38%)  11 (6.21%) 23 (7.77%)  27 (9.12%) 7 (3.95%)  
Desired 
resuscitation? 
   
** 
   
** 
  
*   **   ** 
Yes 281 (93.67%) 84 (48.55%)  244 (93.13%) 121 (57.35%)  123 (87.86%) 242 (72.67%)  166 (93.26%) 199 (67.46%)  190 (64.63%) 174 (97.75%)  
No 19 (6.33%) 89 (51.45%)  18 (6.9%) 90 (42.65%)  17 (12.14%) 91 (27.33%)  12 (6.74%) 96 (32.54%)  104 (35.37%) 4 (2.25%)  
 
22 Weeks (N = 143) 
 Antenatal Steroids  Magnesium sulfate  Tocolytics  GBS PPX  Mode of delivery  
 Yes No  Yes No  Yes No  Yes No  Vaginal Cesarean  
Mother's age 28.9 (5.3) 27.2 (6.1)  27.8 (5.4) 27.7 (6.1)  29.3 (6.4) 27.4 (5.6)  29.4 (5.7) 27.2 (5.9)  27.6 (6.0) 29.3 (4.8)  
Birthweight 349.7 (214.1) 256.8 (198.9) * 348.5 (217.7) 267.1 (200.4)  388.3 (209.6) 270.1 (203.3) * 257.7 (208.3) 317.9 (209.5)  295.9 (207.5) 320.1 (241.1)  
Parity                
Nulliparous 24 (52.17%) 55 (57.29%)  23 (60.53%) 56 (53.85%)  13 (50%) 66 (56.9%)  14 (42.42%) 65 (59.63%)  71 (55.47%) 8 (57.14%)  
Multiparous 22 (47.83%) 41 (42.71%)  15 (39.47%) 48 (46.15%)  13 (50%) 50 (43.10%)  19 (57.58%) 44 (40.37%)  57 (44.53%) 6 (42.86%)  
Race/Ethnicity         *      * 
Caucasian 19 (40.43%) 22 (23.16%)  16 (42.11%) 25 (24.04%)  13 (50%) 28 (24.14%)  13 (38.24%) 28 (25.93%)  34 (26.56%) 7 (50%)  
African American 23 (48.94%) 63 (66.32%)  18 (47.37%) 68 (65.38%)  12 (46.15%) 74 (63.79%)  18 (52.94%) 68 (62.96%)  82 (64.06%) 4 (28.57%)  
Other 5 (10.64%) 10 (10.53%)  4 (10.53%) 11 (10.58%)  1 (3.85%) 14 (12.07%)  3 (8.82%) 12 (11.11%)  12 (9.38%) 3 (21.43%)  
Marital Status   *       *   *   * 
Single 24 (51.06%) 69 (71.88%)  21 (55.26%) 72 (68.57%)  12 (46.15%) 81 (69.23%)  16 (47.06%) 77 (70.64%)  88 (68.22%) 5 (35.71%)  
Married 23 (48.94%) 27 (28.13%)  17 (44.74%) 33 (31.43%)  14 (53.85%) 36 (30.77%)  18 (52.94%) 32 (29.36%)  41 (31.78%) 9 (64.29%)  
Insurance        *   **       
Medicaid 22 (46.81%) 56 (60.22%)  17 (44.74%) 61 (59.8%)  6 (23.08%) 72 (63.16%)  15 (45.45%) 63 (58.88%)  71 (56.35%) 7 (50%)  
Private 20 (42.55%) 24 (25.81%)  18 (47.37%) 26 (25.49%)  18 (69.23%) 26 (22.81%)  14 (42.42%) 30 (28.04%)  37 (29.37%) 7 (50%)  
None 5 (10.64%) 13 (13.98%)  3 (7.89%) 15 (14.71%)  2 (7.69%) 16 (14.04%)  4 (12.12%) 14 (13.08%)  18 (14.29%) 0  
Desire for 
resuscitation?   
** 
   
** 
  
   **   ** 
Yes 38 (82.61%) 31 (33.33%)  31 (81.58%) 38 (37.62%)  16 (61.54%) 53 (46.9%)  24 (72.73%) 45 (42.45%)  55 (44%) 14 (100%)  
No 8 (17.39%) 62 (66.67%)  7 (18.42%) 63 (62.38%)  10 (38.46%) 60 (53.10%)  9 (27.27%) 61 (57.55%)  70 (56%) 0  
23 Weeks (N = 197) 
 Antenatal Steroids  Magnesium sulfate  Tocolytics  GBS PPX  Mode of delivery  
 Yes No  Yes No  Yes No  Yes No  Vaginal Cesarean  
Mother's age 26.9 (6.3) 27.8 (6.7)  26.7 (6.3) 27.7 (6.5)  25.6 (6.1) 27.9 (6.4)  27.0 (6.6) 27.2 (6.2)  27.2 (6.2) 26.9 (6.7%)  
Birthweight 411.9 (244.3) 339.3 (179.8) * 409.6 (246.4) 367.5 (203.4)  462.4 (233.9) 348.1(220.2) ** 391.7 (242.2) 396.4 (225.5)  399.5 (220.6) 391.5 (248.8%)  
Parity                
Nulliparous 76 (53.52%) 23 (41.82%)  65 (55.08%) 34 (43.04%)  40 (58.82%) 59 (45.74%)  47 (55.95%) 52 (46.02%)  57 (48.31%) 42 (53.85%)  
Multiparous 66 (46.48%) 32 (58.18%)  53 (44.92%) 45 (56.96%)  28 (41.18%) 70 (54.26%)  37 (44.05%) 61 (53.98%)  61 (51.69%) 36 (46.15%)  
Race/Ethnicity                   
Caucasian 48 (33.8%) 19 (35.9%)  37 (31.62%) 30 (38.46%)  23 (34.33%) 44 (34.38%)  24 (28.57%) 43 (38.74%)  43 (36.75%) 23 (29.87%)  
African American 84 (59.15%) 28 (52.83%)  72 (61.54%) 40 (51.28%)  41 (61.19%) 71 (55.47%)  55 (65.48%) 57 (51.35%)  62 (52.99%) 50 (64.94%)  
Other 10 (7.04%) 6 (11.32%)  8 (6.84%) 8 (10.26%)  3 (4.48%) 13 (10.16%)  5 (5.95%) 11 (9.91%)  12 (10.26%) 4 (5.19%)  
Marital Status                   
Single 102 (71.83%) 35 (63.6%)  85 (72.03%) 52 (65.82%)  46 (67.65%) 91 (70.54%)  60 (71.43%) 77 (68.14%)  82(69.49%) 55 (70.51%)  
Married 40 (28.17%) 20 (36.4%)  33 (27.97%) 27 (34.18%)  22 (32.35%) 38 (29.46%)  24 (28.57%) 36 (31.86%)  36 (30.51%) 23 (29.49%)  
Insurance                    
Medicaid 92 (65.25%) 33 (60.00%)  78 (66.67%) 47 (59.49%)  45 (67.16%) 80 (62.02%)  54 (64.29%) 71 (63.39%)  71 (60.17%) 54 (70.13%)  
Private 46 (32.62%) 17 (30.91%)  36 (30.77%) 27 (34.18%)  21 (31.34%) 42 (32.56%)  26 (30.95%) 37 (33.04%)  41 (34.75%) 21 (27.27%)  
None 3 (2.13%) 5 (9.09%)  3 (2.56%) 5 (6.33%)  1 (1.49%) 7 (5.43%)  4 (4.76%) 4 (3.57%)  6 (5.08%) 2 (2.6%)  
Desire for 
resuscitation? 
   
** 
   
** 
   
* 
 
 **   ** 
Yes 131 (92.25%) 31 (57.41%)  110 (93.22%) 52 (66.67%)  62 (91.18%) 100 (78.13%)  82 (97.62%) 80 (71.43%)  86 (73.5%) 75 (96.15%)  
No 11 (7.75%) 23 (42.59%)  8 (6.78%) 26 (33.33%)  6 (8.82%) 28 (21.88%)  2 (2.38%) 32 (28.57%)  31 (26.5%) 3 (3.85%)  
24 Weeks (N = 138) 
 Antenatal Steroids  Magnesium sulfate  Tocolytics  GBS PPX  Mode of delivery  
 Yes No  Yes No  Yes No  Yes No  Vaginal Cesarean  
Mother's age 26.3 (5.8) 29.8 (6.9) * 27.0 (6.1) 26.8 (6.3)  26.6 (5.9) 27.2 (6.3)  26.6 (5.6) 27.3 (6.5)  26.1 (5.4) 27.5 (6.5)  
Birthweight 460.4 (241.9) 285 (217.0) * 444.0 (243.6) 422.8 (256.3)  502.3 (235.3) 409.4 (245.0)  448.2 (253.2) 433.7 (239.4)  436.9 (247.1) 442.4 (245.2)  
Parity                
Nulliparous 54 (48.21%) 11 (42.31%)  51 (48.11%) 14 (43.75%)  25 (54.35%) 40 (43.48%)  31 (50.82%) 34 (44.16%)  29 (55.77%) 36 (41.86%)  
Multiparous 58 (51.79%) 15 (57.69%)  55 (51.89%) 18 (56.25%)  21 (45.65%) 52 (56.52%)  30 (49.18%) 43 (55.84%)  23 (44.23%) 50 (58.14%)  
Race/Ethnicity                 
Caucasian 37 (33.33%) 5 (19.23%)  34 (32.38%) 8 (25.00%)  16 (34.78%) 26 (28.57%)  16 (26.67%) 26 (33.77%)  14 (27.45%) 28 (32.56%)  
African American 64 (57.66%) 16 (61.54%)  61 (58.10%) 19 (59.38%)  28 (60.87%) 52 (57.14%)  35 (58.33%) 45 (58.44%)  32 (62.75%) 48 (55.81%)  
Other 10 (9.01%) 5 (19.23%)  10 (9.52%) 5 (15.63%)  2 (4.35%) 13 (14.29%)  9 (15.00%) 6 (7.79%)  5 (9.80%) 10 (11.63%)  
Marital Status                 
Single 78 (69.64%) 17 (65.38%)  70 (66.04%) 25 (78.13%)  33 (71.74%) 62 (67.39%)  40 (65.57%) 55 (71.43%)  39 (75.00%) 56 (65.12%)  
Married 34 (30.36%) 9 (34.62%)  36 (33.96%) 7 (21.88%)  13 (28.26%) 30 (32.61%)  21 (34.43%) 22 (28.57%)  13 (25.00%) 30 (34.88%)  
Insurance         *          
Medicaid 64 (57.66%) 17 (65.38%)  56 (53.33%) 25 (78.13%)  24 (52.17%) 57 (62.64%)  32 (53.33%) 49 (63.64%)  30 (58.82%) 51 (59.30%)  
Private 40 (36.04%) 8 (30.77%)  41 (39.05%) 7 (21.88%)  19 (41.30%) 29 (31.87%)  25 (41.67%) 23 (29.87%)  18 (35.23%) 30 (34.88%)  
None 7 (6.31%) 1 (3.85%)  8 (7.62%) 0  3 (6.52%) 5 (5.49%)  3 (5.00%) 5 (6.49%)  3 (5.88%) 5 (5.81%)  
Desire for 
resuscitation? 







     
Yes 112 (100%) 22 (84.62%)  103 (97.17%) 31 (96.88%)  45 (97.83%) 89 (96.74%)  60 (98.36%) 74 (96.10%)  49 (94.23%) 85 (98.84%)  
No 0 4 (15.38%)  3 (2.83%) 1 (3.13%)  1 (2.17%) 3 (3.26%)  1 (1.64% 3 (3.90%)  3 (5.77%) 1 (1.16%)  
*Significant at <0.05 level.  
**Significant at <0.01 level. 
  
Table 2: 412 newborns with planned resuscitation: clinical characteristics, perinatal interventions and outcomes by delivery week 
 22 0/7 - 22 6/7 
n=40 
23 0/7 - 23 6/7 
n=122 
24 0/7 - 24 6/7 
n=250 
All gestational ages 
n=412 
Perinatal interventions n (%) or mean+SD (range) 
Antenatal steroids (partial or complete course)   14 of 40  (35%) 84 of 122 (69%) 220 of 250 (88%) 318 of 412 (77%) 
Gestational weeks at OB admission  22.4 ±0.3 (22.0-22.8) 23.2 ±0.3 (22.1-23.9) 23.9 ±0.6 (22.0-24.9) 23.6 ±0.7 (22.0-24.9) 
Age at receipt, weeks 22.3 ±0.5 (21.0-22.9) 23.3 ±0.4 (21.7-23.9) 24.0 ±0.5 (22.6-24.9) 23.8 ±0.6 (21.0-24.9) 
Hours between last steroid dose and delivery (of Baby A) 40.9 ±48 (1.4-164) 33.7 ±44(0.33-249) 73.1 ±71 (0-280) 61.3 ±66 (0-280) 
Magnesium for neuroprotection  11 of 40 (28%) 70 of 122 (57%) 197 of 250 (79%) 278 of 412 (68%) 
Tocolytics    6 of 40 (15%) 39 of 122 (32%)   98 of 246 (40%) 143 of 408 (35%) 
Cesarean delivery    2 of 40 (5%) 38 of 120 (32%) 160 of 250 (64%) 200 of 410 (49%) 
Neonatal characteristics  
Gestational weeks at OB admission  22.4 ±0.3 (22.0-22.8) 23.2 ±0.3 (22.1-23.9) 23.9 ±0.6 (22.0-24.9) 23.6 ±0.7 (22.0-24.9) 
Gestational weeks at delivery 22.5 ±0.3 (22.0-22.9) 23.5 ±0.3 (23.0-23.9) 24.4 ±0.3 (24.0-24.9) 24.0 ±0.7 (22.0-24.9) 
Birthweight, g mean+SD (range)* 
    25%ile, 75%ile 
497 ±64 (295-502) 
    457, 547 
574 ±95 (310-880) 
    505,640 
660 ±115 (280-1060) 
    590, 730 
619 ±119 (280-1060) 
    540, 691 
Singleton delivery   26 of 40 (65%) 89 of 122 (73%) 193 of 250 (77%) 308 of 412 (75%) 
Male sex   24 of 40 (60%) 65 of 122 (53%) 130 of 250 (52%) 219 of 412 (53%) 
Neonatal outcomes   
Liveborn 36 of 39 (92%)** 116 of 122 (95%) 247 of 250 (99%) 399 of 411 (97%) 
Survival to NICU discharge    3 of 39 (8%)   42 of 121 (35%) 142 of 239 (59%) 187 of 399 (47%) 
Survival to NICU discharge or transfer to other facility     4 of 40 (10%)   43 of 122 (35%) 153 of 250 (61%) 200 of 412 (49%) 
Liveborn baby surviving to discharge home from NICU   3 of 35 (9%)   42 of 115 (37%) 142 of 247 (58%) 187 of 399 (47%) 
Liveborn baby discharged home or transferred from NICU   4 of 36 (11%)   43 of 116 (37%) 153 of 247 (62%) 200 of 399 (50%) 
*Reflects use estimated fetal weight within one week of birth when birthweight unknown, n=7; missing weights (birth or delivery-week estimated fetal 
weight data), n=17 
**Unknown condition at birth, but did not survive to NICU admission 
 



